Assessing and communicating the risks and benefits of gene transfer clinical trials

Current Opinion in Molecular Therapeutics

Volumn 8, Issue 5, 2006, Pages 384-389

  Kim, Scott Y H ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Clinical trials; Gene transfer; Informed consent; Risk:benefit ratio; Therapeutic misconception

Indexed keywords

ADENOSINE DEAMINASE; ORNITHINE CARBAMOYLTRANSFERASE;

CHRONIC GRANULOMATOUS DISEASE; COLON PERFORATION; COMBINED IMMUNODEFICIENCY; DISORDERS OF AMINO ACID AND PROTEIN METABOLISM; DRUG RESEARCH; EVIDENCE BASED MEDICINE; GENE TRANSFER; HUMAN; INFORMED CONSENT; INTERPERSONAL COMMUNICATION; LEUKEMIA; LYMPHOPROLIFERATIVE DISEASE; MEDICAL ETHICS; PATIENT ATTITUDE; PATIENT MONITORING; PATIENT PARTICIPATION; PREDICTION; PROBABILITY; PROFESSIONAL STANDARD; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; VIRAL GENE DELIVERY SYSTEM;

CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; GENE THERAPY; HUMANS; INFORMED CONSENT; RISK ASSESSMENT;

EID: 33750025076     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Emanuel EJ, Wendler D, Grady C: What makes clinical research ethical? J Am Med Assoc (2000) 283(20):2701-2711.
2. Kimmelman J: Recent developments in gene transfer: Risk and ethics. Br Med J (2005) 330(7482):79-82.
3. Manilla P, Rebello T, Afable C, Lu X, Slepushkin V, Humeau LM, Schoneiy K, Ni Y, Binder GK, Levine BL, Macgregor RR et al: Regulatory considerations for novel gene therapy products: A review of the process leading to the first clinical lentiviral vector. Hum Gene Ther (2005) 16(1):17-25.
4. Mendell JR, Miller A: Gene transfer for neurologic disease: Agencies, policies, and process. Neurology (2004) 63(12):2225-2232.
5. Spink J, Geddes D: Gene therapy progress and prospects: Bringing gene therapy into medical practice: The evolution of International ethics and the regulatory environment. Gene Ther (2004) 11(22):1611-1616.
6. Scharschmidt T, Lo B: Clinical trial design issues raised during recombinant DNA advisory committee review of gene transfer protocols. Hum Gene Ther (2006) 17(4):448-454.
7. King NMP: RAC oversight of gene transfer research: A model worth extending? J Law Med Ethics (2002) 30(3):381-389.
8. High KA: Stakeholders' conference sharpens focus on challenges of clinical gene transfer. Mol Ther (2005) 12(4):581-582.
9. Williams DA: An emerging consensus on recommendations to facilitate clinical gene transfer. Mol Ther (2006) 13(4):637-638.
10. Cavazzana-Calvo M, Hacein-Bey S, Basile G, Gross F, Yvon E, Nusbaum P, Selz F, Hue C, Certain S, Casanova JL, Bousso P et al: Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science (2000) 288(5466):669-672.
11. Aiuti A, Slavin S, Aker M, Ficara F, Deola S, Mortellaro A, Morecki S, Andolfi G, Tabucchi A, Carlucci F, Marinello E et al: Correction of ADASCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science (2002) 296(5577):2410-2413.
12. Gaspar HB, Parsley KL, Howe S, King D, Gilmour KC, Sinclair J, Brouns G, Schmidt M, von Kalle C, Barington T: Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped γ-retroviral vector. The Lancet 364(9452):2181-2187.
13. Ott MG, Schmidt M, Schwarzwaelder K, Stein S, Slier U, Koehl U, Glimm H, Kuhlcke K, Schilz A, Kunkel H, Naundorf S et al: Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med (2006) 12(4):401-409.
14. Kaiser J: American Society of Gene Therapy meeting. Retroviral vectors: A double-edged sword. Science (2005) 308(5729):1735-1736.
15. Abbott A: Questions linger about unexplained gene-therapy trial death. Nat Med (2006) 12(6):567.
16. Tuszynski MH, Thal L, Pay M, Salmon DP. Hol S, Bakay R, Patel P, Blesch A, Vahlsing HL, Ho G, Tong G et al: A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med (2005) 11(5):551-555.
17. Raper SE, Chirmule N, Lee FS, Wivel NA, Bagg A, Gao GP, Wison JM, Batshaw ML: Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab (2003) 80(1-2):148-158.
18. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P, Lim A, Osborne CS, Pawliuk R, Morillon E, Sorensen R. et al: LMO2-assoclated clonal T-cell proliferation in two patients after gene therapy for SCID-X1. Science (2003) 302(5644):415-419.
19. Recombinant DNA Advisory Committee: Conclusions and recommendations of the NIH Recombinant DNA Advisory Committee Gene Transfer Safety symposium: Current perspectives on gene transfer for X-SCID. In: Minutes of the Recombinant DNA Advisory Committee. RAC, National Institutes of Health, Rockville, MD, USA (2005):3-4. http://www4. od.nih.gov/oba/rac/ minutes/RAC_minutes_06-05.pdf
20. Naldini L: Inserting optimism into gene therapy. Nat Med (2006) 12(4):386-388.
21. Borror KC, Office for Human Research Protections: OHRP determination letter to University of Pennsylvania. National Institutes of Health, Rockville, MD, USA (2001): May 17. http://www.hhs.gov/ohrp/ detrm_letrs/may01a.pdf
22. US settles case of gone therapy study that ended with teen's death. University of Pennsylvania Almanac (2005) 51:4-5.
23. Gene therapy clinical trials worldwide. J Gene Med John Wiley and Sons Ltd, London, UK (2006). http://www.wiley.co.uk/genmed/clinical
24. Edelstein ML, Abedi MR, Wixon J, Edelstein RM: Gene therapy clinical trials worldwide 1989-2004 - an overview. J Gene Med (2004) 6(6):597-602.
25. Lyngstadaas A: Status and potential of gene therapy in clinical medicine. Int J Tech Assess Health Care (2002) 18(3):645-674.
26. Horstmann E, McCabe MS, Grochow L, Yamamoto S, Rubinstein L, Budd T, Shoemaker D, Emanuel EJ, Grady C: Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med (2005) 352(9):895-904.
27. Appelbaum PS, Lidz CW, Grisso T: Therapeutic misconception in clinical research: Frequency and risk factors. IRB Ethics & Human Research (2004) 26(2): 1-8.
28. Gene Therapy for Cancer: Questions and Answers. National Cancer Institute, Bethesda, MD, USA (2004). htt://www.cancer.gov/cancertopics/ factsheet/Therapy/gene
29. Pilot study of the use of the human hSlo/maxi-K. gene to treat erectile dysfunction. Recombinant DNA Advisory Committee Minutes of Meeting. Discussion of Human Gene Transfer Protocol #0201-528 (2002):9-13.
30. Agrawal M, Emanuel EJ: Ethics of phase 1 oncology studies: Re-examining the arguments and data. J Am Med Assoc (2003) 290(8):1075-1082.
31. Miller M: Phase I oncology trials. In: Institutional Review Board: Management and Function. Amdur R, Bankert E (Eds), Jones and Bartlett Publishers, Subdury, MA, USA (2002):465-475.
32. King NM, Henderson GE, Churchill LR, Davis AM, Hull SC, Nelson DK, Parham-Vetter PC, Rothschild BB, Easter MM, Wilfond BS: Consent forms and the therapeutic misconception. IRB Ethics & Human Research (2005) 27(1):1-8.
33. Henderson GE, Davis AM, King NMP, Easter MM, Zimmer CR, Rothschild BB, Wilfond BS, Nelson DK, Churchill LR: Uncertain benefit: Investigators' views and communications in early phase gene transfer trials. Mol Ther (2004) 10(2):225-231.
34. Kimmelman J, Levenstadt A: Elements of style: Consent form language and the therapeutic misconception In phase 1 gene transfer trials. Hum Gene Ther (2005) 16(4):502-508.
35. Horng S, Emanuel EJ, Wilfond B, Rackoff J, Martz K, Grady C: Descriptions of benefits and risks in consent forms for phase 1 oncology trials. N Engl J Med (2002) 347(26):2134-2140.
36. Henderson GE, Easter MM, Zimmer C, King NMP, Davis AM, Rothschild BB, Churchill LR, Wifond BS, Nelson DK: Therapeutic misconception in early phase gene transfer trials. Soc Sci Med (2006) 62(1):239-253.
37. Daugherty C, Ratain MJ, Grochowski E, Stocking C, Kodish E, Mick R, Siegler M: Perceptions of cancer patients and their physicians involved in phase I trials. J Clin Oncol (1995) 13(5):1062-1072.
38. Horng S, Grady C: Misunderstanding in clinical research: Distinguishing therapeutic misconception, therapeutic misestimation, and therapeutic optimism. IRB Ethics & Human Research (2003) 25(1):11-16.